Chicago, IL - April 23, 2025:
Three abstracts with preclinical data on ERX-208 and ERX-315 will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 in San Diego. These abstracts will establish ERX-208 as…
https://etira.life/wp-content/uploads/2025/04/Unknown.png14001266Etirahttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngEtira2025-04-24 14:25:482026-01-02 11:01:32Preclinical data on ERX-208 and ERX-315 to be presented at AACR 2025
Adelaide, Australia – March 17, 2025: Etira, a clinical-stage biopharmaceutical company developing new cancer therapies, has now activated a second site for recruitment of patients for the ERX-315-001 clinical trial at Cancer Research South…
https://etira.life/wp-content/uploads/2025/03/image.png6821096Etirahttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngEtira2025-03-17 11:03:202026-01-02 11:03:55Second site activated for ERX-315 trial
Sydney, Australia – February 20, 2025: Etira, a clinical-stage biopharmaceutical company developing new cancer therapies, announced today that a patient has been successfully dosed at Dose Level Three (DL3) of ERX-315 in its Phase 1 trial…
Dallas, TX - December 2, 2024: Etira, a clinical-stage biotechnology company pioneering novel approaches to treating cancer by inducing endoplasmic reticulum stress, today announced the appointment of Etira Co-Founder, Ganesh Raj, M.D., Ph.D.,…
https://etira.life/wp-content/uploads/2024/12/image.png566658Etirahttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngEtira2024-12-02 10:06:322026-01-02 11:08:23Dr. Raj appointed as Etira Chief Medical Officer
Sydney, Australia - November 18, 2024: We are excited to announce that the first patient in our ERX-315-101 Phase 1 clinical trial has successfully received their first doses of ERX-315 at The Kinghorn Cancer Center (TKCC) in Sydney, Australia.…
https://etira.life/wp-content/uploads/2024/11/ER-reduced.png13861070Etirahttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngEtira2024-11-18 10:01:462026-01-02 11:10:37First patient dosed in ERX-315-101 Clinical Trial
Dallas, TX – October 8, 2024: Etira, a clinical-stage biopharmaceutical company developing new cancer therapies, announced the appointment of Annalisa Jenkins, MBBS, FRCP and Justin Stebbing, BM, BCh, MA (oxon), FRCP FRCPath, MD, PhD to…
https://etira.life/wp-content/uploads/2024/10/Board.png516656Etirahttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngEtira2024-10-08 07:14:252026-01-02 11:14:22Drs. Jenkins and Stebbing join Etira Board
Seattle, WA - September 23, 2024: Dr. Surya Viswanadhapalli and Etira founder Dr Ratna Vadlamudi presented a poster titled “The therapeutic potential of ERX-208, a potent inducer of ER stress, in the treatment of ovarian cancer” at the 15th Biennial Ovarian Cancer Research Symposium. The data establishes that ER stress in ovarian cancer (OCa) is targetable and the clinical utility of ERX-208.
https://etira.life/wp-content/uploads/2024/09/Unknown.jpeg8191276Etirahttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngEtira2024-09-23 10:22:362026-03-06 08:23:54Validation of ERX-208 in Ovarian Cancer
Sydney, Australia – September 4, 2024: The Etira team, led by Founder Dr. Ganesh Raj, and the clinical Contract Research Organization Novotech successfully performed the site initiation visit at the Kinghorn Cancer Center (TKCC) in Sydney…
https://etira.life/wp-content/uploads/2024/09/image.png15682324Etirahttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngEtira2024-09-04 10:06:482026-01-02 12:28:10ERX-315-001 SITE INITIATION VISIT @TKCC
Dallas, TX – August 1, 2024: Etira is pleased to announce the approval of the ERX-315 Phase 1 clinical trial by the Australian Human Research Ethics Committee (HREC). This HREC approval enables the start of the clinical trial titled "A Phase…
https://etira.life/wp-content/uploads/2024/08/shutterstock_700277188_edited.jpeg690812Etirahttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngEtira2024-08-01 11:49:472026-01-02 12:26:55ERX-315 CLINICAL TRIAL APPROVED BY HREC
Melbourne, Australia - July 10, 2024: The expansion of Etira partner Medicines Manufacturing Innovation Centre (MMIC) to the Monash Technology Precinct in Clayton was highlighted in the press. This expansion will enable further opportunities…
https://etira.life/wp-content/uploads/2024/07/shutterstock_125779055-scaled.jpg25602127Etirahttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngEtira2024-07-10 12:16:072026-01-02 12:25:40Etira’s Australian partner MMIC expands
Patients must be at least 18 years of age at the time of signing the informed consent.
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
Patients must have histologically or cytologically confirmed solid tumor, primarily including but not limited to breast, ovarian, pancreatic, endometrial, and hepatocellular carcinoma, that is advanced unresectable and/or metastatic disease for whom standard therapies do not exist or are no longer effective
Patients must have measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
Adequate baseline organ function and hematologic function
Life expectancy >3 months
Exclusion criteria
Systemic anti-cancer therapy within 4 weeks of first dose of study drug
Major surgery (as defined by the Investigator) within 4 weeks of first dose of study drug.
Uncontrolled intercurrent illnesses
Known history of LIPA deficiency, such as Wolman disease or Cholesterol ester storage disease.
Preclinical data on ERX-208 and ERX-315 to be presented at AACR 2025
NewsSecond site activated for ERX-315 trial
NewsERX-315 Phase 1 Clinical Trial Update
NewsDr. Raj appointed as Etira Chief Medical Officer
NewsFirst patient dosed in ERX-315-101 Clinical Trial
NewsDrs. Jenkins and Stebbing join Etira Board
NewsValidation of ERX-208 in Ovarian Cancer
NewsERX-315-001 SITE INITIATION VISIT @TKCC
NewsERX-315 CLINICAL TRIAL APPROVED BY HREC
NewsEtira’s Australian partner MMIC expands
News